Granted Patent
B2
US 12,194,076 · App. 17/210,037 · Granted Jan 14, 2025
Methods and compositions for treating myelofibrosis
Assignee:
ACCELERON PHARMA INC.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
In part, the present disclosure relates methods for treating, preventing, or reducing the progression rate and/or severity of myelofibrosis or one or more complications of myelofibrosis (extramedullary hematopoiesis, splenomegaly, anemia, and fibrosis). In certain aspects, the disclosure provides ActRIIB antagonists for use in treating, preventing, or reducing the progression rate and/or severity of one or more complications associated with Janus kinase inhibitor therapy in a patient (e.g., anemia).
Claims (23)
1. A method for treating myelofibrosis, comprising administering to a patient in need thereof an effective amount of: a) ruxolitinib; and b) an ActRIIB polypeptide comprising an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO: 53; wherein the polypeptide comprises an E or a D at the position corresponding to position 79 of SEQ ID NO: 1; and wherein the ActRIIB polypeptide inhibits myostatin and/or GDF11 in a cell-based assay;
wherein the patient is administered one or more blood cell transfusions prior to the start of ActRIIB polypeptide treatment, and wherein the method decreases blood cell transfusions by greater than about 30% for 4 to 8 weeks relative to the equal time prior to the start of the ActRIIB polypeptide treatment.
2. The method of claim 1 , wherein the method decreases one or more of: bone marrow fibrosis, spleen fibrosis, liver fibrosis, lung fibrosis, and lymph node fibrosis.
3. The method of claim 1 , wherein the method increases red blood cell levels in the patient.
4. The method of claim 1 , wherein the method increases hemoglobin levels in the patient.
5. The method of claim 1 , wherein the patient has anemia.
6. The method of claim 5 , wherein the method treats the anemia.
7. The method of claim 1 , wherein the patient is blood cell transfusion-dependent.
8. The method of claim 7 , wherein the method decreases blood cell transfusion burden.
9. The method of claim 1 wherein the patient has primary myelofibrosis.
10. The method of claim 1 wherein the patient has post-polycythemia vera myelofibrosis.
11. The method of claim 1 wherein the patient has post-essential thrombocythemia myelofibrosis.
12. The method of claim 1 , wherein the myelofibrosis is associated with one or more mutations in JAK2.
13. The method of claim 12 , wherein the JAK2 mutation is JAK2V617F.
14. The method of claim 1 , wherein the patient has been treated with a Janus kinase inhibitor.
15. The method of claim 1 , wherein the patient is intolerant of or has an inadequate response to a Janus kinase inhibitor.
16. The method of claim 1 , wherein the patient is further administered hydroxyurea or has previously been treated with hydroxyurea.
17. The method of claim 1 , wherein the patient is intolerant of hydroxyurea or has an inadequate response to hydroxyurea.
18. The method of claim 1 , wherein the ActRIIB polypeptide is administered prior to treatment with ruxolitinib.
19. The method of claim 1 , wherein the ActRIIB polypeptide is administered after treatment with ruxolitinib.
20. The method of claim 1 , wherein the ActRIIB polypeptide is administered concurrently with ruxolitinib.
21. The method of claim 1 , wherein the ActRIIB polypeptide comprises the amino acid sequence of SEQ ID NO: 53.
22. The method of claim 1 , wherein the patient is receiving blood transfusions.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 28, 2022
From: KUMAR, RAVINDRA; SURAGANI, NAGA VENKATA SAI RAJASEKHAR
To: ACCELERON PHARMA INC.
Reel/Frame 060655/0249 →
CHANGE OF NAME
Recorded Jul 28, 2022
From: SURAGANI, NAGA VENKATA SAI RAJASEKHAR
To: SURAGANI, RAJASEKHAR NAGA VENKATA SAI
Reel/Frame 060655/0504 →
Continuity (3)
Provisional Application
62367289
· Jul 27, 2016
References Cited (372)
US 5288931A
· Chang et al.
· 1994
[cited by applicant]
US 6319499B1
· Elliot et al.
· 2001
[cited by applicant]
US 6537966B1
· Duan et al.
· 2003
[cited by applicant]
US 7112660B1
· Domingues et al.
· 2006
[cited by applicant]
US 7208470B2
· Duan et al.
· 2007
[cited by applicant]
US 7572763B2
· Hill et al.
· 2009
[cited by applicant]
US 7595038B2
· Duan et al.
· 2009
[cited by applicant]
US 7612041B2
· Knopf et al.
· 2009
[cited by applicant]
US 7709605B2
· Knopf et al.
· 2010
[cited by applicant]
US 7842663B2
· Knopf et al.
· 2010
[cited by applicant]
US 7842691B2
· Zeldis
· 2010
[cited by applicant]
US 7988973B2
· Sherman
· 2011
[cited by applicant]
US 8058229B2
· Seehra
· 2011
[cited by examiner]
US 8216997B2
· Seehra et al.
· 2012
[cited by applicant]
US 8343933B2
· Knopf et al.
· 2013
[cited by applicant]
US 9505813B2
· Seehra et al.
· 2016
[cited by applicant]
US 20040223966A1
· Wolfman
· 2004
[cited by applicant]
US 20060034831A1
· Tobin
· 2006
[cited by applicant]
US 20100008918A1
· Sherman et al.
· 2010
[cited by applicant]
US 20100015144A1
· Sherman et al.
· 2010
[cited by applicant]
US 20100028332A1
· Sherman
· 2010
[cited by examiner]
US 20130243743A1
· Seehra et al.
· 2013
[cited by applicant]
US 20150148345A1
· Lannutti
· 2015
[cited by examiner]
US 20150276766A1
· Sung et al.
· 2015
[cited by applicant]
US 20150359850A1
· Han et al.
· 2015
[cited by applicant]
US 20150361163A1
· Kumar et al.
· 2015
[cited by applicant]
US 20160046690A1
· Kumar et al.
· 2016
[cited by applicant]
US 20180050085A1
· Kumar et al.
· 2018
[cited by applicant]
US 20200071381A1
· Knopf et al.
· 2020
[cited by applicant]
US 20210038689A1
· Sherman et al.
· 2021
[cited by applicant]
AU 2013221910A1
· 2013
[cited by applicant]
WO WO9204913A1
· 1992
[cited by applicant]
WO WO2004034962A2
· 2004
[cited by applicant]
WO WO2004039948A2
· 2004
[cited by applicant]
WO WO2005028517A2
· 2005
[cited by applicant]
WO WO2006012627A2
· 2006
[cited by applicant]
WO WO2008073292A2
· 2008
[cited by applicant]
WO WO2008076437A2
· 2008
[cited by applicant]
WO WO2008094708A2
· 2008
[cited by applicant]
WO WO2008097541A2
· 2008
[cited by applicant]
WO WO2009158015A2
· 2009
[cited by applicant]
WO WO2010019261A1
· 2010
[cited by applicant]
WO WO2011020045A1
· 2011
[cited by applicant]
WO WO2012027065A2
· 2012
[cited by applicant]
WO WO2012061833A1
· 2012
[cited by applicant]
WO WO2013006437A1
· 2013
[cited by applicant]
WO WO2013059347A1
· 2013
[cited by applicant]
WO WO2014066486A2
· 2014
[cited by applicant]
WO WO2014066487A2
· 2014
[cited by applicant]
WO WO2015143403A1
· 2015
[cited by applicant]
WO WO2015161220A1
· 2015
[cited by applicant]
WO WO2015192111A1
· 2015
[cited by applicant]
WO WO2016090077A1
· 2016
[cited by applicant]
WO WO2016090188A1
· 2016
[cited by applicant]
WO WO2016183280A1
· 2016
[cited by applicant]
WO WO2017079591A2
· 2017
[cited by applicant]
WO WO2017091706A1
· 2017
[cited by applicant]
WO WO2018022762A1
· 2018
[cited by applicant]
WO WO2018231905A1
· 2018
[cited by applicant]
Vannucchi et al., 2017, Blood 129(6):693-703.
[cited by examiner]
Justice et al., 2016, Disease Models & Mechanisms 9:101-103.
[cited by examiner]
Tefferi et al. (2016, Am J Hematol 91(12):1262-1271).
[cited by examiner]
Gerds (2023, J Clin Oncol 41(Suppl 16):abstract 7016).
[cited by examiner]
Suragani et al., 2014, Blood 123(25):3864-3872.
[cited by examiner]
Abandoned U.S. Appl. No. 12/459,204.
[cited by applicant]
Abandoned U.S. Appl. No. 13/218,264.
[cited by applicant]
Abandoned U.S. Appl. No. 15/652,722.
[cited by applicant]
Pending U.S. Appl. No. 16/570,695.
[cited by applicant]
Abandoned U.S. Appl. No. 13/654,191.
[cited by applicant]
Abandoned U.S. Appl. No. 15/413,184.
[cited by applicant]
Abandoned U.S. Appl. No. 15/663,361.
[cited by applicant]
Pending U.S. Appl. No. 16/987,756.
[cited by applicant]
Issued U.S. Pat. No. 8,058,229 (U.S. Appl. No. 12/583,177).
[cited by applicant]
Issued U.S. Pat. No. 8,361,957 (U.S. Appl. No. 13/247,748).
[cited by applicant]
Issued U.S. Pat. No. 9,505,813 (U.S. Appl. No. 13/750,249).
[cited by applicant]
Issued U.S. Pat. No. 10,377,996 (U.S. Appl. No. 15/336,363).
[cited by applicant]
Abandoned U.S. Appl. No. 16/455,301.
[cited by applicant]
Abandoned U.S. Appl. No. 16/795,076.
[cited by applicant]
Issued U.S. Pat. No. 11,168,311 (U.S. Appl. No. 16/795,083).
[cited by applicant]
Issued U.S. Pat. No. 11,155,791 (U.S. Appl. No. 16/795,088).
[cited by applicant]
Issued U.S. Pat. No. 11,162,085 (U.S. Appl. No. 16/808,010.
[cited by applicant]
Pending U.S. Appl. No. 17/243,049.
[cited by applicant]
Issued U.S. Pat. No. 7,842,663 (U.S. Appl. No. 12/012,652).
[cited by applicant]
Issued U.S. Pat. No. 8,343,933 (U.S. Appl. No. 12/893,976).
[cited by applicant]
Issued U.S. Pat. No. 9,399,669 (U.S. Appl. No. 13/730,418).
[cited by applicant]
Issued U.S. Pat. No. 10,259,861 (U.S. Appl. No. 15/201,031).
[cited by applicant]
Abandoned U.S. Appl. No. 16/287,531.
[cited by applicant]
Pending U.S. Appl. No. 17/578,792.
[cited by applicant]
Issued U.S. Pat. No. 8,216,997 (U.S. Appl. No. 12/856,420).
[cited by applicant]
Issued U.S. Pat. No. 8,703,927 (U.S. Appl. No. 13/542,269.
[cited by applicant]
Issued U.S. Pat. No. 9,439,945 (U.S. Appl. No. 14/201,192.
[cited by applicant]
Issued U.S. Pat. No. 9,932,379 (U.S. Appl. No. 15/221,341).
[cited by applicant]
Issued U.S. Pat. No. 10,131,700 (U.S. Appl. No. 15/790,400).
[cited by applicant]
Issued U.S. Pat. No. 10,689,427 (U.S. Appl. No. 16/157,261).
[cited by applicant]
Issued U.S. Pat. No. 10,889,626 (U.S. Appl. No. 16/795,015.
[cited by applicant]
Issued U.S. Pat. No. 10,829,532 (U.S. Appl. No. 16/795,021).
[cited by applicant]
Issued U.S. Pat. No. 10,829,533 (U.S. Appl. No. 16/795,026).
[cited by applicant]
Issued U.S. Pat. No. 10,189,882 (U.S. Appl. No. 14/958,551).
[cited by applicant]
Issued U.S. Pat. No. 10,829,531 (U.S. Appl. No. 16/210,525).
[cited by applicant]
Pending U.S. Appl. No. 15/573,177.
[cited by applicant]
Issued U.S. Pat. No. 11,471,510.
[cited by applicant]
Pending U.S. Appl. No. 17/931,953.
[cited by applicant]
Issued U.S. Pat. No. 9,850,298 (U.S. Appl. No. 14/738,761).
[cited by applicant]
Issued U.S. Pat. No. 10,487,144 (U.S. Appl. No. 15/818,974).
[cited by applicant]
Abandoned U.S. Appl. No. 14/689,477.
[cited by applicant]
Pending U.S. Appl. No. 16/989,505.
[cited by applicant]
Abandoned U.S. Appl. No. 12/459,205.
[cited by applicant]
Abandoned U.S. Appl. No. 15/005,874.
[cited by applicant]
Abandoned U.S. Appl. No. 16/735,833.
[cited by applicant]
Issued U.S. Pat. No. 10,550,170 (U.S. Appl. No. 15/360,588).
[cited by applicant]
Issued U.S. Pat. No. 11,524,990 (U.S. Appl. No. 16/380,196).
[cited by applicant]
Issued U.S. Pat. No. 11,123,430 (U.S. Appl. No. 15/343,757).
[cited by applicant]
Pending U.S. Appl. No. 17/403,539.
[cited by applicant]
Issued U.S. Pat. No. 7,988,973 (U.S. Appl. No. 12/002,872).
[cited by applicant]
Issued U.S. Pat. No. 8,007,809 (U.S. Appl. No. 12/286,333).
[cited by applicant]
Abandoned U.S. Appl. No. 14/664,651.
[cited by applicant]
Pending U.S. Appl. No. 16/919,377.
[cited by applicant]
Agarwal et al., “Bone marrow fibrosis in primary myelofibrosis: pathogenic mechanisms and the role of TGF-Beta,” Stem Cell Investigation, vol. 3:5: 1-10 (2016).
[cited by applicant]
Akhtari, M., “When to Treat Myelodysplastic Syndromes,” Oncology, vol. 25(6): 480-486 (2011).
[cited by applicant]
Al Qaraghuli et al., “Antibody-protein bindng and conformational changes: identifying allosteric signaling pathways to engineer a better effector response,” Nature Scientific Reports, vol. 10:13969 (2020).
[cited by applicant]
Anonymous “Ferritin” www.webmd.com/a-to-z-guides/ferritin?page=2 originally published 2008.
[cited by applicant]
Anonymous “Iron and Thalassemia,” Accessed on the Internet Apr. 3, 2014 at <sickle.bwh.harvard.edu/thaliron.html>. Published Aug. 25, 1997.
[cited by applicant]
Anonymous “Learning about Thalassemia” <http://www.genome.gov/10001221> Accessed on Internet Jul. 9, 2013. Published Jun. 28, 2010.
[cited by applicant]
Anonymous, “Refractory Anaemia with Ring Sideroblasts (MDS-RARS)”, Leukemia Foundation, 3 pages (Year: 2013).
[cited by applicant]
Anonymous. MPN Research Foundation http://www.mpnresearchfoundation.org/; Primary-Myelofibrosis (2011) (7 pages).
[cited by applicant]
Anonymous. “Connective Tissue—Blood & Blood Forming Tissues” http://lifesci.dls.rutgers.edu/-babiarz/bloodtx.htm (2014).
[cited by applicant]
Anonymous: “A Phase 2, Multicenter, Open-Label Study of the Safety and Efficacy of Luspatercept in Subjects with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis and Anemia With or Without RBC Tansfusion Depen…
[cited by applicant]
Attie, et al., “A Phase 1 Study of ACE-536, A Regulator of Erythroid Differentiation, in Healthy Volunteers,” American Journal of Hematology, vol. 89(7): 766-770 (2014).
[cited by applicant]
Bartoszko et al., (Comparison of the Impact of Two Different Definitions of Red-Cell Transfusion Dependence of the Natural History of Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF). Abstract. Blood, vol…
[cited by applicant]
Barzi, et al., “Myelodysplastic Syndromes: A Practical Approach to Diagnosis and Treatment,” Cleveland Clinic Journal of Medicine, vol. 77(1): 37-44 (2010).
[cited by applicant]
Beguin et al., “Ferrokinetic Study of Splenic Erthropoiesis: Relationships Among Clinial Diagnosis, Myelofibrosis, Splenomegaly, and Extramedullary Erthropoiesis,” Am. J. Hematol., vol. 32(2): 123-128 (1989).
[cited by applicant]
Bhattacharya et al., Impact of genetic variation on three dimensional structure and function of proteins; PLOS One; vol. 12(3): e0171355, pp. 1-22 (2017).
[cited by applicant]
Bejar, et al., “Recent Developments in Myelodysplastic Syndromes,” Blood, vol. 124(18): 2793-2803 (2014).
[cited by applicant]
Bejar et al., “Validation of a prognostic model and the impact of SF3B1, DNMT3A, and other mutations in 289 genetically characterized lower risk MDS patient samples,” Abstract. Blood, vol. 114(21); 118(21) p. 443; Abstr…
[cited by applicant]
Bennett, et al., “Proposals for the Classification of the Myelodysplastic Syndromes,” British Journal of Hematology, vol. 51: 189-199 (1982).
[cited by applicant]
Biankin, et al., “Pancreatic Cancer Genomes Reveal Aberrations in Axon Guidance Pathway Genes,” Nature, vol. 491: 399-405 (2012).
[cited by applicant]
Bottomley, et al., “Siderbloastic Anemia: Diagnosis and Management,” Hematology Oncology Clinic of North America, vol. 28: 653-670 (2014).
[cited by applicant]
Bradley et al., “Visions & Reflections (Minireview); Myostatin as a therapeutic target for musculoskeletal disease,” Cell. Mol. Life Sci., vol. 65: 2119-2124 (2008).
[cited by applicant]
Breda et al., “Modulators of Erythropoiesis”, Hematology—Oncology Clinics of North America, vol. 28(2): 375-386 (2014).
[cited by applicant]
The Cancer Genome Atlas Network: Comprehensive Molecular Portraits of Human Breast Tumours,Nature, vol. 490: 61-70 (2012).
[cited by applicant]
Cao, et al., “Recent Advances in Beta-thalassemias,” Pediatric Reports, vol. 3(e17): 65-78 (2011).
[cited by applicant]
Camaschella, Clara, “Hereditary Sideroblastic Anemias: Pathophysiology, Diagnosis, and Treatment,” Seminars in Hematology, vol. 46(4): 371-377 (2009).
[cited by applicant]
Camaschella, C., “Recent Advances in the Understanding of Inherited Sideroblastic Anemia”, British Journal of Haematology, vol. 143:27-38 (2008).
[cited by applicant]
Casadevall, et al., “Health, Economic, and Quality-of-Life Effects of Erythropoietin and Granulocyte Colony-Stimulating Factor for the Treatment of Myelodysplastic Syndromes: A Randomized, Controlled Trial,” Blood, vol.…
[cited by applicant]
Cazzola, et al., “Quantitative Evaluation of Erythropoietic Activity in Dysmyelopoietic Syndromes,” British Journal of Hematology, vol. 50: 55-62 (1982).
[cited by applicant]
Cazzola, et al., “The Genetic Basis of Myelodysplasia and Its Clinical Relevance,” Blood, vol. 122(25): 4021-4034 (2013).
[cited by applicant]
Cervantes et al., “New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment,” Blood Journal, vol. 113(13): 2895-2901 (2009).
[cited by applicant]
PDB ID: 1S4Y_A, Chain A, Activin Receptor Type IIb Precursor [
[cited by applicant]
PDB ID: 4FAO_E, Chain E, Activin Receptor Type-2b [
[cited by applicant]
Chen et al., “Mapping the Domain(s) Critical for the Binding of Human Tumor Necrosis Factor-alpha to Its Two Receptors”, The Journal of Biological Chemistry, vol. 270(6): 2874-2878 (1995).
[cited by applicant]
Chesnais, et al., “Spliceosome Mutations in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia,” Impact Journals: Oncotarget, vol. 3(11): 1284-1293 (2012).
[cited by applicant]
Cheson, et al., “Clinical Application and Proposal for Modification fo the International Working Group (IWG) Response Criteria in Myelodysplasia,” Blood, vol. 108(2): 419-425 (2006).
[cited by applicant]
Cheson, et al., “Report of an International Working Group to Standardize Response Criteria for Myelodysplastic Syndromes,” Blood, vol. 96(12): 3671-3674 (2000).
[cited by applicant]
Coerver, K.A., et al., “Activin Signaling through Activin Receptor Type II Causes the Cachexia-Like Symptoms in Inhibin-Deficient Mice,” Molecular Endocrinology, 10(5):534-543 (1996).
[cited by applicant]
Cuijpers et al., “Recent advances in the understanding of iron overload in sideroblastic myelodysplastic syndrome,” British J. Haematology, vol. 49: 322-333 (2010).
[cited by applicant]
Czader et al., “Chapter 27: Myelodysplastic/myeloproliferative neoplasms.” in: Churchill Livingstone, Blood and Bone Marrow Pathology., London, England, pp. 391-406 (2011).
[cited by applicant]
Davidoff, et al., “Patterns of Erythropoiesis-Stimulating Agent Use Among Medicare Beneficiaries with Myelodysplastic Syndromes and Consistency with Clinical Guidelines,” Leukemia Research, vol. 37: 675-680 (2013).
[cited by applicant]
Dayyani, et al., “Cause of Death in Patients with Lower-Risk Myelodysplastic Syndrome,” Cancer, vol. 116: 2174-2179 (2010).
[cited by applicant]
Demetri, et al., “Quality-of-life Benefit in Chemotherapy Patients Treated With Epoetin Alfa Is Independent of Disease Response or Tumor Type: Results From a Prospective Community Oncology Study,” Journal of Clinical On…
[cited by applicant]
Dolatshad, et al., “Disruption of SF3B1 Results in Deregulated Expression and Splicing of Key Genes and Pathways in Myelodysplastic Syndrome Hematopoietic Stem and Progenitor Cells,” Leukemia, vol. 29: 1092-1103 (2015).
[cited by applicant]
Dore et al., “Serum erythropoietin levels in thalassemia intermedia,” Annals of Hematology, vol. 67:183-186 (1993).
[cited by applicant]
Edwards et al., The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein, BLyS. Journal of Molecular Biology, vol. 334:103-118 (2003).
[cited by applicant]
Esposito, et al., “Labile Plasma Iron in Iron Overload: Redox Activity and Susceptibility to Chelation,” Blood, vol. 102(7): 2670-2677 (2003).
[cited by applicant]
Estey, E. H., “Current Challenges in Therapy of Myelodysplastic Syndromes,” Current Opinion in Hematology, vol. 10: 60-67 (2003).
[cited by applicant]
Fenaux, et al., “Efficacy of Azacitidine Compared with that of Conventional Care Regimens in the Treatment of Higher-Risk Myelodysplastic Syndromes: A Randomised, Open-Label, Phase III Study,” The Lancet: Oncology, vol.…
[cited by applicant]
Fenton et al., Rheostat positions: A new classification of protein positions relevant to pharmacogenomics Medicinal Chemistry Research, vol. 29:1133-1145 (2020).
[cited by applicant]
Fields et al., Expert Opin. Investig Drugs vol. 22(1): 87-101 (2013).
[cited by applicant]
Furney, et al., “SF3B1 Mutations Are Associated with Alternative Splicing in Uveal Melanoma,” Cancer Discovery, vol. 3(10): 1122-1129 (2013).
[cited by applicant]
Galanello, et al., “Combined Iron Chelation Therapy,” Annals of the New York Academy of Sciences, vol. 1202: 79-86 (2010).
[cited by applicant]
Garcia-Manero, et al., “Hypomethylating Agents and Other Novel Strategies in Myelodysplastic Syndromes,” Journal of Clinical Oncology, vol. 29(5): 516-523 (2011).
[cited by applicant]
Giagounidis, et al., “Outcomes in RBC Transfusion-Dependent Patients with Low-/Intermediate-1-Risk Myelodysplastic Syndromes with Isolated Deletion 5q Treated with Lenalidomide: A Subset Analysis from the MDS-004 Study,…
[cited by applicant]
Glaspy, et al., “Impact of Therapy with Epotin Alfa on Clinical Outcomes in Patients with Nonmyeloid Malignancies During Cancer Chemotherapy in Community Oncology Practice,” Journal of Clinical Oncology, vol. 15(3): 121…
[cited by applicant]
Glaspy, J. A., “Erythropoietin in Cancer Patients,” The Annual Review of Mediine, vol. 60: 181-192 (2009).
[cited by applicant]
Goldberg, et al., “Incidence and Clinical Complications of Myelodysplastic Syndromes Among United States Medicare Beneficiaries,” Journal of Clinical Oncology, vol. 28(17): 2847-2852 (2010).
[cited by applicant]
Greenberg, et al., “Myelodysplastic Syndromes: Clinical Practice Guidelines in Oncology,” Journal of the National Comprehensive Cancer Network, vol. 9(1): 30-56 (2011).
[cited by applicant]
Greenberg, et al., “Treatment of Myelodysplastic Syndrome Patients with Erythropoietin with or without Granulocyte Colony-Stimulating Factor: Results of a Prospective Randomized Phase 3 Trial by the Eastern Cooperative …
[cited by applicant]
Guerra et al., “Lack of GDF11 Does Not Ameliorate Erythropoiesis in Beta-Thalassemia and Does Not Prevent the Activity of the Trap-Ligand RAP-536,” Blood, vol. 132:165 (6 pages) 2018.
[cited by applicant]
Guerra et al., “Lack of GDF11 does not improve anemia or prevent the activity of RAP-536 in a mouse model of beta-thalassemia,” Blood, vol. 134(6): 568-572 (2019).
[cited by applicant]
Haferlach et al., “Landscape of genetic lesions in 944 patients with myelodysplastic syndromes,” Leukemia, vol. 28: 241-247 (2014).
[cited by applicant]
Haidar et al., “Paraspinal extramedullary hematopoiesis in patients with thalassemia intermedia,” Eur Spine J., vol. 19: 871-878 (2010).
[cited by applicant]
Haidet et al., “Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors,” PNAS, vol. 105(11):4318-4322 (2008).
[cited by applicant]
Harrison, C.A., et al., “Antagonists of activin signaling: mechanisms and potential biological applications,” Trends in Endocrinology and Metabolism, 16(2):73-78 (2005).
[cited by applicant]
Harrison et al., “JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis,” The New England Journal of Medicine, vol. 366(9): 787-798 (2012).
[cited by applicant]
Hellstrom-Lindberg, et al., “A Validated Decision Model for Treating the Anaemia of Myelodysplastic Syndromes with Erythropoietin + Granulocyte Colony-Stimulating Factor: Significant Effects on Quality of Life,” British…
[cited by applicant]
Heuser and Ganser, “Recombinant human erythropoietin in the treatment of nonrenal anemia,” Ann. Hematology, vol. 85:69-78 (2006).
[cited by applicant]
Hill et al., “The Myostatin Propeptide and the Follistatin-related Gene Are Inhibitory Binding Proteins of Myostatin in Normal Serum,” The Journal of Biological Chemistry, vol. 277(43): 40735-40741 (2002).
[cited by applicant]
Horl, et al., “European Best Practice Guidelines 14-16 Inadequate Response to Epoetin,” Nephrology Dialysis Transplantation, vol. 15(Supp. 4): 43-50 (2000).
[cited by applicant]
Hsieh, Matthew M, et al., “HIF-prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques,” Blood, 110(6):2140-2147 (2007).
[cited by applicant]
Ishikawa et al., “A Basic Study on the Effects of Erythropoietin (EPO): The Effects of EPO on Hemopoietic Organs and Blood Cell Components,” J. Med. Soc. of Toho University, vol. 38(4): 528-536 (1991).
[cited by applicant]
Itoh et al., “Sideroblastic anemia associated with multiple myeloma in Turner's syndrome,” Abstract. Internal medicine Tokyo, Japan, vol. 31(4): 483-485 (1992).
[cited by applicant]
Jacobs et al., “European Best Practice Guidelines 5 Target haemoglobin,” Nephrology Dialysis Transplantation, vol. 15[Suppl 4]: 15-19 (2000).
[cited by applicant]
Je, et al., “Mutational Analysis of Splicing Machinery Genes SF3B1, U2AF1 and SRSF2 in Myelodysplasia and Other Common Tumors,” International Journal of Cancer, vol. 133: 260-266 (2013).
[cited by applicant]
Jelkmann, et al., “The Erythropoietin Receptor in Normal and Cancer Tissues,” Critical Reviews in Oncology/Hematology, vol. 67: 39-61 (2008).
[cited by applicant]
Juneja, et al., “Prevalence and Distribution of Ringed Sideroblasts in Primary Myelodysplastic Syndromes,” Journal of Clinical Pathology, vol. 36: 566-569 (1983).
[cited by applicant]
Justice et al., “Using the mouse to model human disease: increasing validity and reproducibility,” Disease, Models & Mechanisms, vol. 9:101-103 (2016).
[cited by applicant]
Kalinowski, et al., “The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer,” Pharmacological Reviews, vol. 57(4): 547-583 (2005).
[cited by applicant]
Kantarjian, et al., “Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia,” Journal of Clinical Oncology, vol. 28(3): 437-444 (2010).
[cited by applicant]
Kantarjian, et al., “Survival Advantage with Decitabine Versus Intensive Chemotherapy in Patients with Higher Risk Myelodysplastic Syndrome: Comparison with Historical Experience,” Cancer, vol. 109(6): 1133-1137 (2007).
[cited by applicant]
Keohane et al., “Ruxolitinib for myelofibrosis,” Clinical Investigation, vol. 2(10): 1023-1031 (2012).
[cited by applicant]
Koury, et al., “Erythropoietin Retards DNA Breakdown and Prevents Programmed Death in Erythroid Progenitor Cells,” Science, vol. 248: 378-381 (1990).
[cited by applicant]
Krapf, et al., “Arterial Hypertension Induced by Erythropoietin and Erythropoiesis-Stimulating Agents (ESA),” Clinical Journal of the American Society of Nephrology, vol. 4: 470-480 (2009).
[cited by applicant]
Kumar Mishra and Tiwari, “Iron Overload in Beta Thalassaemia Major and Intermedia Patients,” MAEDICA—Journal of Clinical Medicine, vol. 8(4): 328-332 (2013).
[cited by applicant]
Lee, Se-Jin, “Quadrupling Muscle Mass in Mice by Targeting TGF-Beta Signaling Pathways,” PLoS One, Issue 2(8):e789 (2007). (7 pages).
[cited by applicant]
Leitch, H. A., “Controversies Surrounding Iron Chelation Therapy For MDS,” Blood Reviews, vol. 25: 17-31 (2011).
[cited by applicant]
Liboi, et al., “Erythropoietin Receptor Signals Both Proliferation and Erythroid-Specific Differentiation,” Proceedings of the National Academy of Sciences, vol. 90: 11351-11355 (1993).
[cited by applicant]
Lin, et al., “NUP98-HOXD13 Transgenic Mice Develop a Highly Penetrant, Severe Myelodysplastic Syndrome that Progresses to Acute Leukemia,” Blood, vol. 106(1): 287-295 (2005).
[cited by applicant]
List, et al., “Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion,” The New England Journal of Medicine, vol. 355(14): 1456-1465 (2006).
[cited by applicant]
List et al., “188—Myelodysplastic Syndrome.” in: Saunders, Goldman's Cecil Medicine., Philadelphia, PA (2012), pp. 1200-1203.
[cited by applicant]
Liu, et al., “Suppression of Fas-FasL Coexpression by Erythropoietin Mediates Erythroblast Expansion During the Erythropoietic Stress Response In Vivo,” Blood, vol. 108(1): 123-133 (2006).
[cited by applicant]
Liu, Xinmin, “Myelofibrosis”, China Medical Encyclopedia Internatl Medicine, vol. 3, Military Medical Science Press: pp. 117-120 (Oct. 31, 2008). (translated).
[cited by applicant]
Lodberg et al., “A follistatin-based molecule increases muscle and bone mass without affecting the red blood cell count in mice”, The FASEB Journal, vol. 33:6001-6010 (2019).
[cited by applicant]
Lyons, et al., “Comparison of 24-Month Outcomes in Chelated and Non-Chelated Lower-Risk Patients with Myelodysplastic Syndromes in a Prospective Registry,” Leukemia Research, vol. 38: 149-154 (2014).
[cited by applicant]
Lyons, et al., “Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients with Myelodysplastic Syndromes,” Journal of Clinical Oncology, vol. 27(11): 1850-1856 (2009).
[cited by applicant]
Magga et al., Systemic Blockade of ACVR2B Ligands Protects Myocardium from Acute Ischemia-Reperfusion Injury, Molecular Therapy, vol. 27(3): 600-610 (2019).
[cited by applicant]
Maguer-Satta et al., “During hematopoiesis, expression of FLRG, a novel activin A ligand, is regulated by TGF-beta”, Experimental Hematology, vol. 29: 301-308 (2001).
[cited by applicant]
Maguer-Satta, V. and Rimokh, R., “FLRG, member of the follistatin family, a new player in hematopoiesis”, Molecular and Cellular Endocrinology, vol. 225: 109-118 (2004).
[cited by applicant]
Malcovati, et al., “Clinical Significance of SF3B1 Mutations in Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms,” Blood, vol. 118(24): 6239-6246 (2011).
[cited by applicant]
Malcovati et al., Granulocyte JAK2 (V617F) mutation status in myeloid neoplasms with ringed sideroblasts. Abstract. Blood, vol. 108(11) Part 1, 256A (2006).
[cited by applicant]
Malcovati, et al., “Impact of the Degree of Anemia on the Outcome of Patients with Myelodysplastic Syndrome and its Integration into the WHO classification-based Prognostic Scoring System (WPSS),” Haematologica, vol. 96…
[cited by applicant]
Malcovati, et al., “Prognosis Factors and Life Expectancy in Myelodysplastic Syndromes Classified According to WHO Criteria: A Basis for Clinical Decision Making,” Journal of Clinical Oncology, vol. 23(30): 7594-7603 (2…
[cited by applicant]
Malcovati, et al., “Refractory Anemia with Ring Sideroblasts,” Best Practice & Research Clinical Haematology, vol. 26: 377-387 (2013).
[cited by applicant]
Malcovati, et al., “Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis,” Blood, vol. 114(17): 3538-3545 (2009).
[cited by applicant]
Meng et al., SF3B1 gene mutation and myelodysplastic syndromes with ring sideroblast excess-review. Abstract. Zhongguo Shiyan Xueyexue Zazhi, vol. 21(4): 1088-1090 (2013).
[cited by applicant]
Merck Manual. Iron-Utilization Anemias (Sideroblastic Anemias), pp. 1150-1151 (1992).
[cited by applicant]
Mesa et al, “The Myelofibrosis Symptom Assessment Form (MFSAF): An Evidence-based Brief Inventory to Measure Quality of Life and Symptomatic Response to Treatment in Myelofibrosis,” Leuk Res. vol. 33(9): 1199-1203 (2009…
[cited by applicant]
Mesa et al., “A phase 2, multicenter open-label study of the safety and efficacy of luspatercept in subjects with myeloproliferative neoplasm (MPN)-associated myelofibrosis and anemia with or without RBC transfusion dep…
[cited by applicant]
Moyo, et al., “Erythropoiesis-Stimulating Agents in the Treatment of Anemia in Myelodysplastic Syndromes: A Meta-Analysis,” Annals of Hematology, vol. 87: 527-536 (2008).
[cited by applicant]
Mufti, et al, “Diagnosis and Classification of Myelodysplastic Syndrome: International Working Group on Morphology of Myelodysplastic Syndrome (IWGM-MDS) Consensus Proposals for the Definition and Enumeration of Myelobl…
[cited by applicant]
Murphy, et al., “Serum erythropoietin at diagnosis in low grade myelodysplastic syndrome correlates with both red cell zinc protoporphyrin and serum lactic dehydrogenase (LDH) and may reflect severity of ineffective ery…
[cited by applicant]
Nguyen et al., FDA-approved ruxolitinib in patients with myelofibrosis: The Stanford experience. Blood, vol. 120(21), Abstract No. 1747, 2012.
[cited by applicant]
Negrin, et al., “Maintenance Treatment of the Anemia of Myelodysplastic Syndromes with Recombinant Human Granulocyte Colony-Stimulating Factor and Erythropoietin: Evidence for In Vivo Synergy,” Blood, vol. 87(10): 4076-…
[cited by applicant]
Nemeth, E., “Hepcidin in Beta-thalassemia,” Annals of the New York Academy of Sciences, vol. 1202: 31-35. Published Aug. 2, 2010.
[cited by applicant]
Nisli et al., “Serum Erythropoietin Levels in Patients with Beta Thalassemia Major and Intermedia,” Pediatric Hematology and Oncology, vol. 14(2): 161-167 (2009).
[cited by applicant]
Okamura, Takashi, “Anemia associated with myelofibrosis,” Current Therapy, vol. 18(5): 842-847 (2000).
[cited by applicant]
Oliva, et al., “A Review of Anemia as a Cardiovascular Risk Factor in Patients with Myelodysplastics Syndromes,” American Journal of Blood Research, vol. 1(2): 160-166 (2011).
[cited by applicant]
Ornstein, et al., “Combination Strategies in Myelodysplastic Syndromes,” International Journal of Hematology, vol. 95: 26-33 (2012).
[cited by applicant]
Ozcan et al., “Review of therapeutic options and the management of patients with myelodysplastic syndromes,” Expert Review Hematol, vol. 6:165-189 (2013).
[cited by applicant]
Papaemmanuil, et al., “Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts,” The New England Journal of Medicine, vol. 365(15): 1384-1395 (2011).
[cited by applicant]
Park, et al., “Predictive Factors of Response and Survival in Myelodysplastic Syndrome Treated with Erythropoietin and G-CSF: The GFM Experience,” Blood, vol. 111(2): 574-582 (2008).
[cited by applicant]
Parmeggiani et al., “Alpha interferon in the treatment of symptomatic myelofibrosis with myeloid metaplasia,” Eur. J. Haematol. vol. 39:2238-232 (1987).
[cited by applicant]
Pereria et al., X-linked sideroblasticanemia (XLSA): Two new mutations identified in males. Abstract. Haematologica, vol. 95, Supp. Suppl. 2: 716-717, Abstract No. 1854 (2010).
[cited by applicant]
Platzbecker et al., A phase 2, ascending dose study of ACE-536 to treat anemia in low/intermediate-1 risk MDS patients, The PACE-MDS study; in: Proceedings from the 12th International Symposium on Myelodysplastic Syndro…
[cited by applicant]
Poosaria et al., “Computational De Novo Design of Antibodies Binding to a Peptide with High Affinity,” Biotechn. Bioeng., vol. 114(6): 1331-1342 (2017).
[cited by applicant]
Rachmilewitz et al., “How I treat thalassemia,” Blood, vol. 118(13): 3479-3488 (2011).
[cited by applicant]
Rawn, J., “The Silent Risks of Blood Transfusion,” Current Opinion in Anaethesiology, vol. 21: 664-668 (2008).
[cited by applicant]
Raya, et al., “Refractory anemia with ringed sideroblasts associated with thrombocytosis: comparative analysis of marked with non-marked thrombocytosis, and relationship with JAK2 V617F mutational status,” International…
[cited by applicant]
Reichel et al., “Antibody-based strategies for the detection of Luspatercept (ACE-536) in human serum,” Drug Test Anal., vol. 9: 1721-1730 (2017).
[cited by applicant]
Sako, D., et al., “Characterization of the Ligand Binding Functionality of the Extracellular Domain of Activin Receptor Type IIB,” The Journal of Biological Chemistry, 285(27): 21037-21048 (2010).
[cited by applicant]
Santini, et al., “Hepcidin Levels and Their Determinants in Different Types of Myelodysplastic Syndromes,” PLoS One, vol. 6(8): 1-8 (2011).
[cited by applicant]
Santini, V., “Clinical Use of Erythropoietic Stimulating Agents in Myelodysplastic Syndromes,” The Oncologist, vol. 16(Supp. 3): 35-42 (2011).
[cited by applicant]
Santini, V., “Treatment of Low-Risk Myelodysplastic Syndrome: Hematopoietic Growth Factors Erythropoietins and Thrombopoietins,” Seminars in Hematology, vol. 49(4): 295-303 (2012).
[cited by applicant]
Sheftel et al., “Mitochondrial Iron Metabolism and Sideroblastic Anemia,” Acta Haematol, vol. 122: 120-133 (2009).
[cited by applicant]
Shen, et al., “DNA Methylation Predicts Survival and Response to Therapy in Patients with Myelodysplastic Syndromes,” Journal of Clinical Oncology, vol. 28(4): 605-613 (2010).
[cited by applicant]
Shiozaki, M., et al., “In Vivo Treatment With Erythroid Differentiation Factor (EDF / Activin A) Increases Erythroid Precursors (CFU-E and BFU-E) in Mice,” Biochemical and Biophysical Research Communications, 165(3):115…
[cited by applicant]
Siah, et al., “Normal Iron Metabolism and the Pathophysiology of Iron Overload Disorders,” The Clinical Biochemist Reviews, vol. 27: 5-16 (2006).
[cited by applicant]
Slichter, S. J., “Evidence-Based Platelet Transfusion Guidelines,” American Society of Hematology Education Program: 172-178 (2007).
[cited by applicant]
Sloand, et al., “Alemtuzumab Treatment of Intermediate-1 Myelodysplasia Patients is Associated with Sustained Improvement in Blood Counts and Cytogenetic Remissions,” Journal of Clinical Oncology, vol. 28(35): 5166-5173…
[cited by applicant]
Socolovsky, et al., “Ineffective Erythropoiesis in Stat5a-/-5b-/—Mice Due to Decreased Survival of Early Erythroblasts,” Blood, vol. 98(12): 3261-3273 (2001).
[cited by applicant]
Steensma, D. P., “Hematopoietic Growth Factors in Myelodysplastic Syndromes,” Seminars in Oncology, vol. 38(5): 635-647 (2011).
[cited by applicant]
Steensma, et al., “The Myelodysplastic Syndromes: Diagnosis and Treatment,” Mayo Clinic Proceedings, vol. 81(1): 104-130 (2006).
[cited by applicant]
Steensma, et al., “When is Iron Overload Deleterious, and When and How Should Iron Chelation Therapy Be Administered in Myelodysplastic Syndromes?,” Best Practice & Research Clinical Haematology, vol. 26: 431-444 (2013).
[cited by applicant]
Suh and Lee, “Myostatin Inhibitors: Panacea or Predicament for Musculoskeletal Disorders?”, J. Bone Metab. vol. 27(3): 151-165 (2020).
[cited by applicant]
Supplementary EP Search Report EP 17 83 5212, dated Feb. 18, 2020.
[cited by applicant]
Surgani et al., “Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine Beta-thalassemia,” vol. 123(25): 3864-3872 (2014).
[cited by applicant]
Surag ani, et al., “Transforming Growth Factor-Beta Superfamily Ligand Trap ACE-536 Corrects Anemia By Promoting Late-Stage Erythropoiesis,” Nature Medicine, vol. 20(4): 408-417 (2014).
[cited by applicant]
Tanno, T. and Miller, J.L., “Iron Loading and Overloading due to Ineffective Erythropoiesis,” Advances in Hematology, vol. 2010; Article ID 358283, Chapter 2 (Abstract); A179; 136-138 (2010).
[cited by applicant]
Temraz, et al., “Iron Overload and Chelation Therapy in Myelodysplastic Syndromes,” Critical Reviews in Oncology/Hematology, vol. 91: 64-73 (2014).
[cited by applicant]
Terpos et al., “Prolonged Administration of Erythropoietin Increases Response Rate in Myelodysplastic Syndromes: a Phase II Trial in 281 Patients”, British Journal of Haematology, vol. 118(1):174-180 (2002).
[cited by applicant]
Tokuriki et al., “Stability effects of mutations and protein evolvability,” Current Opinion in Structural Biology, vol. 19: 596-604 (2009).
[cited by applicant]
Vardiman, et al., “The 2008 Revision of the World Health Organization (WHO) Classification of Myeloid Neoplasms and Acute Leukemia: Rationale and Important Changes,” Blood, vol. 114(5): 937-951 (2009).
[cited by applicant]
Vogiatzi et al., “Bone Disease in Thalassemia: A Frequent and Still Unresolved Problem,” Journal of Bone and Mineral Research, vol. 24: 543-557 (2008).
[cited by applicant]
Wang, et al., “SF3B1 and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia,” The New England Journal of Medicine, vol. 365(26): 2497-2506 (2011).
[cited by applicant]
Ward, R., “An update on disordered iron metabolism and iron overload,” Hematology, vol. 15(5): 311-317 (2010).
[cited by applicant]
Weatherall, et al., “Red Cells I: Inherited Anaemias,” The Lancel, vol. 355: 1169-1175 (2000).
[cited by applicant]
Webb, et al., “The Development and Application of Small Molecule Modulators of SF3b as Therapeutic Agents for Cancer,” Drug Discovery Today, vol. 18(1-2): 43-49 (2013).
[cited by applicant]
Whatley, et al., “C-Terminal Deletions in the ALAS2 Gene Lead to Gain of Function and Cause X-Linked Dominant Protoporphyria Without Anemia or Iron Overload”, American Journal of Human Genetics, vol. 83:408-414 (2008).
[cited by applicant]
Wu et al., “Follistatin-like 1 attenuates differentiation and survival of erythroid cells through Smad2/3 signaling”, Biochemical and Biophysical Research Communications, vol. 455(4): 711-716 (2015).
[cited by applicant]
Zeidan, et al., “There's Risk, and Then There's RISK: The Latest Clinical Prognostic Risk Stratification Models in Myelodysplastic Syndromes,” Current Hematologic Malignancy Reports, vol. 8: 351-360 (2013).
[cited by applicant]
Alaoui-Ismaili, et al., “Design of second generation therapeutic recombinant bone morphogenetic proteins,” Cytokine & Growth Factor Reviews; vol. 20(5-6): 501-507 (2009).
[cited by applicant]
ASH Annual Meeting; “557—A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia” (3 pages) Dec. 9, 2019.
[cited by applicant]
Barosi et al., “Therapeutic approaches in myelofibrosis,” Expert Opinion on Pharmacotherapy, vol. 12(10): 1597-1611 (2011).
[cited by applicant]
Barosi et al., “Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and t…
[cited by applicant]
Baxter et al., “Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders,” Lancet, vol. 365: 1054-1061 (2005).
[cited by applicant]
Bernier et al., Pharmacological chaperone action on G-protein-coupled receptors, Curr. Opin. Pharmacol., vol. 4(5):528-533 (2004).
[cited by applicant]
Bunn, “Drug-induced autoimmune red-cell aplasia,” The New England Journal of Medicine, vol. 346(7): 522-523 (2002).
[cited by applicant]
Carbuccia et al., “Mutations of ASXL1 gene in myeloproliferative neoplasms,” Leukemia, vol. 23: 2183-2186 (2009).
[cited by applicant]
Cervantes, Francisco, “Myelofibrosis: biology and treatment options,” European Journal of Haematology, vol. 79(Suppl. 68): 13-17 (2007).
[cited by applicant]
Celgene: “A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence,” ClinicalTrial…
[cited by applicant]
Delanty et al., “Erythropoietin-associated hypertensive posterior leukoencephalopathy,” Neurology, vol. 49: 686-689 (1997).
[cited by applicant]
Delhommeau et al., “Mutation in TET2 in Myeloid Cancers,” The New England Journal of Medicine, vol. 360(22): 2289-2301 (2009).
[cited by applicant]
Ernst et al., “Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders,” Nature Genetics, vol. 42(8): 722-726 (2010).
[cited by applicant]
Fang et al., “Early chronic kidney disease-mineral bone disorder stimulates vascular calcification,” Kidney International, vol. 85(1): 142-150 (2014).
[cited by applicant]
Faoro et al., “Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia,” European Journal of Haematology, vol. 74: 117-120 (2005).
[cited by applicant]
Gerds et al., “A phase 2 study of luspatercept in patients with myelofibrosis-associated anemia”, Data Embase, Database Accession No. EMB-630316332 (2019). (3 pages).
[cited by applicant]
Grand et al., “Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms,” Blood, vol. 113(24): 6182-6192 (2009).
[cited by applicant]
Green et al., “Somatic Mutations of IDH1 and IDH2 in the Leukemic Transformation of Myeloproliferative Neoplasms,” The New England Journal of Medicine, vol. 362(4): 369-370 (2010).
[cited by applicant]
Gupta et al., “Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors,” Blood, vol. 120(7): 1367-1379 (2012).
[cited by applicant]
Guo, et al., “Protein Tolerance to Random Amino Acid Change,” Proc. Natl. Acad. Sci. USA, 101(25): 9205-9210 (Jun. 22, 2004). Epub Jun. 14, 2004.
[cited by applicant]
Harrison et al., “JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis”, New England Journal of Medicine, vol. 366(9): 787-798 (2012).
[cited by applicant]
Hasselbalch et al., “Successful Treatement of Anemia in Idiopathic Myelofibrosis With Recombinant Human Erythropoietin,” American Journal of Hematology, vol. 70: 92-99 (2002).
[cited by applicant]
Ho et al., “Practical Management of myelofibrosis with ruxolitinib,” Royal Australasian College of Physicians, Internal Medical Journal, vol. 45(12): 1221-1230 (2015).
[cited by applicant]
Horl et al., “European Best Practice Guidelines 17-18 Adverse effects,” Nephrology Dialysis Transplantation, vol. 15(suppl. 4): 51-56 (2000).
[cited by applicant]
Hussein et al., “Conventional cytogenetics in myelofibrosis: literature review and discussion,” European Journal of Haematology, vol. 82: 329-338 (2009).
[cited by applicant]
Hussein et al., “International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis,” Blood, vol. 115(3): 496-499 (2010).
[cited by applicant]
Jager et al., “Deletions of the transcription factor Ikaros in myeloproliferative neoplasms,” Leukemia, vol. 24: 1290-1298 (2010).
[cited by applicant]
James et al., “A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera,” Nature, vol. 434: 1144-1148 (2005).
[cited by applicant]
Kralovics et al., “A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders,” The New England Journal of Medicine, vol. 352(17): 1779-1790 (2005).
[cited by applicant]
Kvasnicka et al., “Prodromal myeloproliferative neoplasms: The 2008 WHO classification,” American Journal of Hematology, vol. 85: 62-69 (2010).
[cited by applicant]
Lasho et al., “SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival,” Blood, vol. 120(20): 4168-4171 (2012).
[cited by applicant]
Levine et al., “Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis,” Cancer Cell, vol. 7: 387-397 (2005).
[cited by applicant]
Li, Qinglei et al., “Prevention of cachexia-like syndrome development and reduction of tumor pr ogression in inhibin-deficient mice following adminisration of a chimeric activin receptor type II-murine Fc protein,” Mole…
[cited by applicant]
Manoharan et al., “The Reticulin Content of Bone Marrow in Acute Leukaemia in Adults,” British Journal of Haematology, vol. 43: 185-190 (1979).
[cited by applicant]
Martinez-Trillos et al., “Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients,” Annals of Hematology, vol. 89(12): 1233-1237 (2010).
[cited by applicant]
Mascarenhas et al., “Advances in myelofibrosis: a clinical case approach,” Haematologica, vol. 98(10): 1499-1509 (2013).
[cited by applicant]
Mascarenhas et al., “Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib,” Current Medical Chemistry, vol. 19: 4399-4413 (2012).
[cited by applicant]
Oh et al., “Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms,” Blood, vol. 116(6): 988-992 (2010).
[cited by applicant]
Passamonti et al., “A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment),” Blood, vol. 115…
[cited by applicant]
Patnaik et al., “Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival,” European Journal of Haema…
[cited by applicant]
Pikman et al., “MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia,” PLOS Medicine, vol. 3:e270 (2006).
[cited by applicant]
Platzbecker et al., “ACE-536 Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results for a Phase 2 Study,” Blood, vol. 124(21)…
[cited by applicant]
Quintas-Cardama et al., “Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond,” Nature Reviews, vol. 10: 127-140 (2011).
[cited by applicant]
Scott et al., “JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis,” The New England Journal of Medicine, vol. 356(5): 459-468 (2007).
[cited by applicant]
Singbartl, “Adverse events of erythropoietin in long-term and in acute/short-term treatment,” The Clinical Investigator, vol. 72(suppl 6), S36-S43 (1994).
[cited by applicant]
Stegelmann et al., “A Phase-Ib/II Study of Ruxolitinib Plus Pomalidomide in Myelofibrosis”, Database Biosis Biosciences Information Service; Database accession No. PREV201600270701 (2015) (4 pages).
[cited by applicant]
Tefferi, Ayalew, “Myelofibrosis with Myeloid Metaplasia,” Medical Progress, vol. 342(17): 1255-1265 (2000).
[cited by applicant]
Tefferi et al., “CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients,” Leukemia, vol. 28: 1494-1500 (2014).
[cited by applicant]
Tefferi et al., “CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons,” Leukemia, vol. 28: 1472-1477 (2014).
[cited by applicant]
Tefferi et al., “Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc inte…
[cited by applicant]
Tefferi, A., “How I treat myelofibrosis,” Blood, vol. 117(13): 3494-3504 (2011).
[cited by applicant]
Tefferi et al., “CME Information: Primary myelofibrosis: 2014 update on diagnosis, risk-stratification and management,” American Journal of Hematology, vol. 89(9): 915-925 (2014).
[cited by applicant]
Tefferi et al., “Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions,” Leukemia, vol. 21(8): 1827-1828 (2007).
[cited by applicant]
Tefferi et al., “Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis-prognostic relevance is independent of IPSS o…
[cited by applicant]
Tefferi et al., “Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients,” Blood, vol. 118: 4595-4598 (2011).
[cited by applicant]
Tefferi et al., “IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F,” Leukemia, vol. 26: 475-480 (2012).
[cited by applicant]
Tefferi et al., “IDH1 and IDH2 mutation studies in 1473 patients with chronic- , fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis,” Leukemia, vol. 24: 1302-1309 (2010).
[cited by applicant]
Thapaliya et al., “International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens,” Ameri…
[cited by applicant]
Thiele et al., “European consensus on grading bone marrow fibrosis and assessment of cellularity,” Haematologica, vol. 90(8): 1128-1132 (2005).
[cited by applicant]
Ulloa-Aguirre et al. “Pharmacologic Rescue of Conformationally-Defective Proteins: Implications for the Treatment of Human Disease,” Traffic, vol. 5; 821-837 (2004).
[cited by applicant]
Vannucchi, Alessandro M., “Management of Myelofibrosis,” American Society of Hematology: Current Issues in Myeloproliferative Neoplasms: 222-230 (2011).
[cited by applicant]
Verstovsek et al., “A Double-Blind Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis,” New England Journal of Medicine: 366(9): 799-807 (2012).
[cited by applicant]
Xing et al., “Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice,” Blood, vol. 111(10): 5109-5117 (2008).
[cited by applicant]
Casu et al., “Hepcidin agonists as therapeutic tools”, Blood, vol. 131:1790-1794 (2018).
[cited by applicant]
Gerds et al., “Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis: Results from the ACE-536-MF-001 study,” Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Al…
[cited by applicant]
Tefferi, “CME Information: Primary myelofibrosis: 2017 update on diagnosis, risk-stratification and management,” American Journal of Hematology, vol. 91(12): 1261-1271 (2016).
[cited by applicant]
Di Tucci et al., “Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade(R), ICL670)”, Eur. J. Haematology, vol. 78:540-542 (2007).
[cited by applicant]
Georgiades et al., “Typical and Atypical Presentations of Extramedullary Hemopoiesis,” Am. J. Radio., vol. 179:1230-1343 (2002).
[cited by applicant]
Wang et al., “Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features”, Leukemia, vol. 20:1641-1644 (2…
[cited by applicant]